DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Foretinib
Foretinib
Adaptive Stress Signaling in Targeted Cancer Therapy Resistance
Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) Through Multikinase Inhibition Jessica D
Novel Targets and Strategies in Glioblastomas
Gefitinib Or Lapatinib with Foretinib Synergistically Induce a Cytotoxic Effect in Melanoma Cell Lines
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
The New-Generation Selective ROS1/NTRK Inhibitor DS-6051B Overcomes Crizotinib Resistant ROS1- G2032R Mutation in Preclinical Models
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
Phase II Trial of Single-Agent Foretinib (GSK1363089) in Patients with Recurrent Or Metastatic Squamous Cell Carcinoma of the Head and Neck
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Acquired Resistance to BRAF Inhibition in BRAFV600E Mutant Gliomas
Foretinib Is a Potent Inhibitor of Oncogenic ROS1 Fusion Proteins
A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimet
Committed to Patients. Making Every Moment Count. People Living with Cancer Aren’T Just Patients
Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma Claudia C
Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors
Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives
Top View
Natural Products Booklet
Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild
A Phase I/II Multicenter Study of Single-Agent Foretinib As First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma Thomas C.C
Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
Template for a Phase I/II CTIMP
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor
Identification of Endogenous Function and Substrate-Dependent Interactions of Organic Cation Transporter 1
VEGF Pathway-Targeting Drugs Induce Evasive Adaptation by Activation of Neuropilin-1/Cmet in Colon Cancer Cells
Cancer Therapeutics
Download Product Insert (PDF)
An Enabling Technology to Compare Kinase Compound Residency Time
Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1
Foretinib Overcomes Entrectinib Resistance Associated with The
Study Protocol
Prevalence of Androgen Receptor Positivity in Triple Negative Breast
Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma Of
Structural Insight Into Selectivity and Resistance Profiles of ROS1 Tyrosine Kinase Inhibitors
RTK Inhibitors in Melanoma: from Bench to Bedside
WO 2017/065602 Al 20 April 2017 (20.04.2017) P O P C T
BCAN-NTRK1 Fusion
Implications of Interactions Between Tyrosine Kinase Inhibitors and Human Solute Carriers in Cancer Therapy
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
PF-06463922 Is a Potent and Selective Next-Generation ROS1/ALK Inhibitor Capable of Blocking Crizotinib-Resistant ROS1 Mutations
Antitumor Drugs and Their Targets
Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer Ryohei Katayama1, Yuka Kobayashi1,2, Luc Friboulet3,4, Elizabeth L
Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
Ut Scc 110A Ut Scc 21 Ut Scc 49 Ut Scc 74A
Downregulating Oncogenic Receptor
Cell Death-Based Treatment of Lung Adenocarcinoma Tatiana V
Sunitinib for Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: a Multicenter Retrospective Turkish Oncology Group Trial
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
2013-11-23-Apasl-Stc
Enzyme Inhibitors Enzymes Are Biological Catalysts That Drive Various Reactions Within a Cell
Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
Effect of Foretinib on Matrix Metalloproteinase-2 (MMP2) Page 20 Expression in Glioblastoma,” Research in Molecular Medicine (RMM), Vol
Theranostics Generation of Hepatic Spheroids Using Human Hepatocyte
Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild Type Melanoma Cell Lines
Resistance Mechanisms to Targeted Therapy in BRAF-Mutant Melanoma - a Mini Review
Tyrosine Kinase Receptors in Oncology
Abbreviated Title: Phase I/II XL184 in Mcrpc